# Anomalous Angiogenesis in Retina

^{*}

## Abstract

**:**

## 1. Introduction

## 2. Materials and Methods

#### 2.1. Cellular Potts Model

#### 2.2. Continuum Fields at the Extracellular Scale

^{−1}, D

_{f}= 0.036 mm

^{2}/h, ν = 0.6498/h, S = 5 × 10

^{−7}pg/µm

^{2}(corresponding to 50 ng/mL for a sample with a 10 µm height [40,41]), and Γ = 0.02 pg/(µm

^{2}h) is the maximum amount of VEGF that could be consumed by a cell per hour [21,37,42]. In Equation (2), the VEGF source due to 320 the hypoxia caused by drusen and photoreceptors is

#### Durotaxis

#### 2.3. Signaling Processes and Cell Dynamics

#### 2.4. Retinal Configuration and Onset of Angiogenesis

_{pv}that may initiate sprouts and establish an external VEGF activation threshold for the sprouts to start. The parent vessels are randomly placed at the rectangle 0 < x < L, 0 < y < 0.3L = 120 µm and the concentration of external VEGF satisfies Equation (2). The 2 µm wide BM is a segment placed at y = 246 µm [5,43] and it is followed by RPE cells with interspersed drusen, which have Gaussian sources of VEGF representing hypoxic areas. These sources placed at y = 249 µm are farther than 100 µm from the choriocapillaries, which is consistent with the criterion for hypoxia to occur. New sprouts grow from the initial points only if the external VEGF concentration in them is larger than a threshold. The described CPM causes the sprouts to advance toward the drusen and they may or may not pass BM and RPE attracted by the VEGF sources at the photoreceptors.

_{photo}sources of VEGF associated with photoreceptors which are equally spaced on the x axis at y = 388 µm. We ignore the photoreceptors’ outer segments and their dynamics. As in the case of the sources associated with drusen, these VEGF sources are represented by Gaussian functions centered at (${x}^{{p}_{i}}$, ${y}^{{p}_{i}}$ = 388 µm) [45]. The holes divide BM into N

_{drusen}+ 1 pieces. Once VEGF sources are activated, new sprouts can start from the parent vessels at their predetermined sites if the external VEGF concentration there surpasses the activation threshold. VEGF sources stop emitting it when they are reached by ECs.

## 3. Results

#### 3.1. Impaired Adhesion

#### 3.1.1. Adhesion between RPE and BM

#### 3.1.2. RPE–RPE and EC–EC Adhesion

#### 3.2. Sources of VEGF

#### 3.3. Notch Signaling

## 4. Discussion

## 5. Conclusions

## Supplementary Materials

## Author Contributions

## Funding

## Institutional Review Board Statement

## Informed Consent Statement

## Data Availability Statement

## Conflicts of Interest

## Abbreviations

2D | Two Dimensional |

AMD | Age-related Macular Degeneration |

BM | Bruch’s membrane |

CNV | Choroid Neo Vascularization |

CPM | Cellular Potts Model |

EC | Endothelial Cell |

ECM | Extra Cellular Matrix |

EMT | Epithelial to Mesenchymal Transition |

MC | Monte Carlo |

MCTS | Monte Carlo Time Step |

RPE | Retinal Pigmentation Epithelium |

VEGF | Vessel Endothelial Growth Factor |

## References

- Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.G.; Klein, R.; Cheng, C.-Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health
**2014**, 2, 106–116. [Google Scholar] [CrossRef] [Green Version] - Jonas, J.B. Comment. Global prevalence of age-related macular degeneration. Lancet Glob. Health
**2014**, 2, e65–e66. [Google Scholar] [CrossRef] [Green Version] - Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med.
**2008**, 358, 2606–2617. [Google Scholar] [CrossRef] [Green Version] - Nivison-Smith, L.; Milston, R.; Madigan, M.; Kalloniatis, M. Age-Related Macular Degeneration: Linking Clinical Presentation to Pathology. Optom. Vision Sci.
**2014**, 91, 832–848. [Google Scholar] [CrossRef] [PubMed] - Manjunath, V.; Taha, M.; Fujimoto, J.G.; Duker, J.S. Choroidal Thickness in Normal Eyes Measured Using Cirrus-HD Optical Coherence Tomography. Am. J. Ophthalmol.
**2010**, 150, 325–329.e1. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Coscas, G.; Lupidi, M.; Coscas, F. Atlas of OCT: Angiography in AMD. Comparison with Multimodal Imaging; Societé Francaise de Retine, L’Europeenne d’Editions: Paris, France, 2015. [Google Scholar]
- Laforest, T.; Künzi, M.; Kowalczuk, L.; Carpentras, D.; Behar-Cohen, F.; Moser, C. Transscleral optical phase imaging of the human retina. Nat. Photonics
**2020**, 14, 439–445. [Google Scholar] [CrossRef] - Gariano, R.F.; Gardner, T.W. Retinal angiogenesis in development and disease. Nature
**2005**, 438, 960–966. [Google Scholar] [CrossRef] - Fruttiger, M. Development of the retinal vasculature. Angiogenesis
**2007**, 10, 77–88. [Google Scholar] [CrossRef] [PubMed] - Scott, A.; Powner, M.B.; Gandhi, P.; Clarkin, C.; Gutmann, D.H.; Johnson, R.S.; Ferrara, N.; Fruttiger, M. Astrocyte-Derived Vascular Endothelial Growth Factor Stabilizes Vessels in the Developing Retinal Vasculature. PLoS ONE
**2010**, 5, e11863. [Google Scholar] [CrossRef] [Green Version] - Selvam, S.; Kumar, T.; Fruttiger, M. Retinal vasculature development in health and disease. Prog. Retin. Eye Res.
**2018**, 63, 1–19. [Google Scholar] [CrossRef] - Carmeliet, P.F. Angiogenesis in life, disease and medicine. Nature
**2005**, 438, 932–936. [Google Scholar] [CrossRef] - Carmeliet, P.; Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature
**2005**, 436, 193–200. [Google Scholar] [CrossRef] - Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature
**2011**, 473, 298–307. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Tonnesen, M.G.; Feng, X.; Clark, R.A. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc.
**2000**, 5, 40–46. [Google Scholar] [CrossRef] [Green Version] - Figg, W.D.; Folkman, J. Angiogenesis. An Integrative Approach from Science to Medicine; Springer: Berlin/Heidelberg, Germany, 2008. [Google Scholar]
- Gerhardt, H.; Golding, M.; Fruttiger, M.; Ruhrberg, C.; Lundkvist, A.; Abramsson, A.; Jeltsch, M.; Mitchell, C.; Alitalo, K.; Shima, D.; et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol.
**2003**, 161, 1163–1177. [Google Scholar] [CrossRef] [PubMed] - Hellström, M.; Phng, L.K.; Hofmann, J.J.; Wallgard, E.; Coultas, L.; Lindblom, P.; Alva, J.; Nilsson, A.-K.; Karlsson, L.; Gaiano, N.; et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature
**2007**, 445, 776–780. [Google Scholar] [CrossRef] - Jolly, M.K.; Boareto, M.; Lu, M.; Onuchic, J.N.; Clementi, C.; Ben-Jacob, E. Operating principles of Notch-Delta-Jagged module of cell-cell communication. New J. Phys.
**2015**, 17, 055021. [Google Scholar] [CrossRef] [Green Version] - Page, D.J.; Thuret, R.; Venkatraman, L.; Takahashi, T.; Bentley, K.; Herbert, S.P. Positive Feedback Defines the Timing, Magnitude, and Robustness of Angiogenesis. Cell Rep.
**2019**, 27, 3139–3151. [Google Scholar] [CrossRef] [PubMed] - Vega, R.; Carretero, M.; Travasso, R.D.M.; Bonilla, L.L. Notch signaling and taxis mechanims regulate earlystage angiogenesis: A mathematical and computational model. PLoS Comput. Biol.
**2020**, 16, e1006919. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Gebala, V.; Collins, R.; Geudens, I.; Phng, L.-K.; Gerhardt, H. Blood flow drives lumen formation by inverse membrane blebbing during angiogenesis in vivo. Nat. Cell Biol.
**2016**, 18, 443–450. [Google Scholar] [CrossRef] [Green Version] - Franco, C.A.; Jones, M.L.; Bernabeu, M.O.; Geudens, I.; Mathivet, T.; Rosa, A.; Lopes, F.M.; Lima, A.P.; Ragab, A.; Collins, R.T.; et al. Dynamic endothelial cell rearrangements drive developmental vessel regression. PLoS Biol.
**2015**, 13, e1002125. [Google Scholar] - Szymborska, A.; Gerhardt, H. Hold me, but not too tight–endothelial cell-cell junctions in angiogenesis. Cold Spring Harb. Perspect. Biol.
**2018**, 10, a029223. [Google Scholar] [CrossRef] - Dufraine, J.; Funahashi, Y.; Kitajewski, J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene
**2008**, 27, 5132–5137. [Google Scholar] [CrossRef] [Green Version] - Booij, J.C.; Baas, D.C.; Beisekeeva, J.; Gorgels, T.G.M.F.; Bergen, A.A.B. The dynamic nature of Bruch’s membrane. Prog. Ret. Eye Res.
**2010**, 29, 1–18. [Google Scholar] [CrossRef] - Mammadzada, P.; Corredoira, P.M.; André, H. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: A gene therapy perspective. Cell. Mol. Life Sci.
**2020**, 77, 819–833. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Gehrs, K.M.; Anderson, D.H.; Johnson, L.V.; Hageman, G.S. Age-related macular degeneration–emerging pathogenetic and therapeutic concepts. Ann. Med.
**2009**, 38, 450–471. [Google Scholar] [CrossRef] - Radeke, M.J.; Radeke, C.M.; Shih, Y.-H.; Hu, J.; Bok, D.; Johnson, L.V.; Coffey, P.J. Restoration of mesenchymal retinal pigmented epithelial cells by TGFβ pathway inhibitors: Implications for age-related macular degeneration. Genome Med.
**2015**, 7, 58. [Google Scholar] [CrossRef] [Green Version] - Shu, D.Y.; Butcher, E.; Saint-Geniez, M. EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration. Int. J. Mol. Sci.
**2020**, 21, 4271. [Google Scholar] [CrossRef] - Tamiya, S.; Liu, L.; Kaplan, H.J. Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Investig. Ophthalmol. Vis. Sci.
**2010**, 51, 2755–2763. [Google Scholar] [CrossRef] [Green Version] - Roberts, P.A.; Gaffney, E.A.; Luthert, P.J.; Foss, A.J.E.; Byrne, H.M. Mathematical and Computational Models of the Retina in Health, Development and Disease. Prog. Retin. Eye Res.
**2016**, 53, 48–69. [Google Scholar] [CrossRef] - Flower, R.W.; von Kerczek, C.; Zhu, L.; Eggleton, E.C.; Topoleski, L.D.T. Theoretical Investigation of the Role of Choriocapillaris Blood Flow in Treatment of Subfoveal Choroidal Neovascularization Associated WithAge-related Macular Degeneration. Am. J. Opthtalmol.
**2001**, 132, 85–93. [Google Scholar] [CrossRef] - Davies, A.E.; Williams, R.L.; Lugano, G.; Pop, S.R.; Kearns, V.R. In vitro and computational modelling of drug delivery across the outer blood-retinal barrier. Interface Focus
**2020**, 10, 20190132. [Google Scholar] [CrossRef] - Shirinifard, A.; Glazier, J.A.; Swat, M.; Gens, J.S.; Family, F.; Jiang, Y.; Grossniklaus, H.E. Adhesion Failures Determine the Pattern of Choroidal Neovascularization in the Eye: A Computer Simulation Study. PLoS Comput. Biol.
**2012**, 8, e1002440. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Graner, F.; Glazier, J.A. Simulation of Biological Cell Sorting Using a Two-Dimensional Extended Potts Model. Phys. Rev. Lett.
**1992**, 69, 2013–2016. [Google Scholar] [CrossRef] - Bauer, A.L.; Jackson, T.L.; Jiang, Y. A Cell-Based Model Exhibiting Branching and Anastomosis during Tumor-Induced Angiogenesis. Biophys. J.
**2007**, 92, 3105–3121. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Van Oers, R.F.M.; Rens, E.G.; La Valley, D.J.; Reinhart-King, C.A.; Merks, R.M.H. Mechanical cell-matrix feedback explains pairwise and collective endothelial cell behavior in vitro. PLoS Comput. Biol.
**2014**, 10, el003774. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Boareto, M.; Jolly, M.K. Ben-Jacob, E.; Onuchic, J.N. Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision. Proc. Natl. Acad. Sci. USA
**2015**, 112, E3836–E3844. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Arima, S.; Nishiyama, K.; Ko, T.; Arima, Y.; Hakozaki, Y.; Sugihara, K.; Koseki, K.; Uchijima, H.; Kurihara, Y.; Kurihara, H. Angiogenic morphogenesis driven by dynamic and heterogeneous collective endothelial cell movement. Development
**2011**, 138, 4763–4776. [Google Scholar] [CrossRef] [Green Version] - Sugihara, K.; Nishiyama, K.; Fukuhara, S.; Uemura, A.; Arima, S.; Kobayashi, R.; Köhn-Luque, A.; Mochizuki, N.; Suda, T.; Ogawa, H.; et al. Autonomy and Non-autonomy of Angiogenic Cell Movements Revealed by Experiment-Driven Mathematical Modeling. Cell Rep.
**2015**, 13, 1814–1827. [Google Scholar] [CrossRef] [Green Version] - Mantzaris, N.V.; Webb, S.; Othmer, H.G. Mathematical modeling of tumor-induced angiogenesis. J. Math. Biol.
**2004**, 49, 111–187. [Google Scholar] [CrossRef] - Bai, H.X.; Mao, Y.; Shen, L.; Xu, X.L.; Gao, F.; Zhang, Z.B.; Li, B.; Jonas, J.B. Bruch’s membrane thickness in relationship to axial length. PLoS ONE
**2017**, 12, e0182080. [Google Scholar] [CrossRef] [Green Version] - Friberg, T.R.; Bilonick, R.A.; Peter Brennen, P. Is Drusen Area Really So Important? An Assessment of Risk of Conversion to Neovascular AMD Based on Computerized Measurements of Drusen. Investig. Opthalmology Vis. Sci.
**2012**, 53, 1742–1751. [Google Scholar] [CrossRef] [PubMed] - Poh, S.; Tham, Y.; Chee, M.L.; Dai, W.; Majithia, S.; Soh, Z.D.; Fenwick, E.K.; Tao, Y.; Thakur, S.; Rim, T.H.; et al. Association between Macular Thickness Profiles and Visual Function in Healthy Eyes: The Singapore Epidemiology of Eye Diseases (SEED) Study. Sci. Rep.
**2020**, 10, 6142. [Google Scholar] [CrossRef] [PubMed] - Gullapalli, V.K.; Sugino, I.K.; Van Patten, Y.; Shah, S.; Zarbin, M.A. Impaired RPE survival on aged submacular human Bruch’s membrane. Exp. Eye Res.
**2005**, 80, 235–248. [Google Scholar] [CrossRef] [PubMed] - Imamura, Y.; Noda, S.; Hashizume, K.; Shinoda, K.; Yamaguchi, M.; Uchiyama, S.; Shimizu, T.; Mizushima, Y.; Shirasawa, T.; Tsubota, K. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: A model of age-related macular degeneration. Procs. Natl. Acad. Sci. USA
**2005**, 103, 11282–11287. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Simó, R.; Villarroel, M.; Corraliza, L.; Hernández, C.; Garcia-Ramírez, M. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier–implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol.
**2010**, 2010, 190724. [Google Scholar] [CrossRef] - Ramos, J.R.D.; Travasso, R. Carvalho, J. Capillary network formation from dispersed endothelial cells: Influence of cell traction, cell adhesion, and extracellular matrix rigidity. Phys. Rev. E
**2018**, 97, 012408. [Google Scholar] [CrossRef] - Bhutto, I.A.; McLeod, D.S.; Hasegawa, T.; Kim, S.Y.; Merges, C.; Tong, P.; Lutty, G.A. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res.
**2006**, 82, 99–110. [Google Scholar] [CrossRef] [Green Version] - Fogli, S.; Del Re, M.; Rofi, E.; Posarelli, C.; Figus, M.; Danesi, R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye
**2018**, 32, 1010–1020. [Google Scholar] [CrossRef] [Green Version] - West, J.W.; Sagert, J.G.; Bessette, P.H.; Lowman, H.B.; Stagliano, N.E.; Vasiljeva, O.; Menendez, E.-E.M. Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies and Methods of Use Thereof. U.S. Patent 10,301,380, 28 May 2019. Available online: https://patents.google.com/patent/US9127053B2/en (accessed on 17 December 2020).
- Sierra, R.A.; Trillo-Tinoco, J.; Mohamed, E.; Yu, L.; Achyut, B.R.; Arbab, A.; Bradford, J.W.; Osborne, B.A.; Miele, L.; Rodriguez, P.C. Anti-Jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance. Cancer Res.
**2017**, 77, 5628–5638. [Google Scholar] [CrossRef] [Green Version] - Zhou, M.; Yu, Q.; Huang, K.; Mahov, S.; Eslami, A.; Maier, M.; Lohmann, C.P.; Navab, N.; Zapp, D.; Knoll, A.; et al. Towards Robotic-assisted Subretinal Injection: A Hybrid Parallel-Serial Robot System Design and Preliminary Evaluation. IEEE Trans. Ind. Electron.
**2020**, 67, 6617–6628. [Google Scholar] [CrossRef] - Parolini, B.; Nava, U.; Palmieri, M.; Lucente, A.; Finzi, A.; Frisina, R. RPE and Choroid Transplantation in Macular Degeneration. In Macular Surgery; Chang, A., Mieler, W.F., Ohji, M., Eds.; Springer Nature: Cham, Switzerland, 2020; pp. 401–422. [Google Scholar]
- Cheng, D.L.; Greenberg, P.B.; Borton, D.A. Advances in retinal prosthetic research: A systematic review of engineering and clinical characteristics of current prosthetic initiatives. Curr. Eye Res.
**2017**, 42, 334–347. [Google Scholar] [CrossRef] - Maya-Vetencourt, J.F.; Ghezzi, D.; Antognazza, M.R.; Colombo, E.; Mete, M.; Feyen, P.; Desii, A.; Buschiazzo, A.; Di Paolo, M.; Di Marco, S.; et al. A fully organic retinal prosthesis restores vision in a rat model of degenerative blindness. Nat. Mater.
**2017**, 16, 681–689. [Google Scholar] [CrossRef] [PubMed] - Tang, J.; Qin, N.; Chong, Y.; Diao, Y.; Yiliguma; Wang, Z.; Xue, T.; Jiang, M.; Zhang, J.; Zheng, G. Nanowire arrays restore vision in blind mice. Nat. Commun.
**2018**, 9, 786. [Google Scholar] [CrossRef] [PubMed] [Green Version] - Gagliardi, G.; Ben M’Barek, K.; Goureau, O. Photoreceptor cell replacement in macular degeneration and retinitis pigmentosa: A pluripotent stem cell-based approach. Prog. Ret. Eye Res.
**2019**, 71, 1–25. [Google Scholar] [CrossRef] - Singh, M.S.; Park, S.S.; Albini, T.A.; Canto-Soler, M.V.; Klassen, H.; MacLaren, R.E.; Takahashi, M.; Nagiel, A.; Schwartz, S.D.; Bharti, K. Retinal stem cell transplantation: Balancing safety and potential. Prog. Retin. Eye Res.
**2020**, 75, 100779. [Google Scholar] [CrossRef] [PubMed] - Stieger, K.; Lorenz, B. RPE and gene therapy. In Retinal Pigment Epithelium in Health and Disease; Klettner, A.K., Dithmar, S., Eds.; Springer Nature: Cham, Switzerland, 2020; pp. 265–279. [Google Scholar]
- Jemni-Damer, N.; Guedan-Duran, A.; Cichy, J.; Lozano-Picazo, P.; Gonzalez-Nieto, D.; Perez-Rigueiro, J.; Rojo, F.; Guinea, G.V.; Virtuoso, A.; Cirillo, G.; et al. First steps for the development of silk fibroin-based 3D biohybrid retina for age-related macular degeneration (AMD). J. Neural Eng.
**2020**, 17, 055003. [Google Scholar] [CrossRef] - Bonilla, L.L.; Carpio, A.; Trenado, C. Tracking collective cell motion by topological data analysis. PLoS Comput. Biol.
**2020**, 16, e1008407. [Google Scholar] [CrossRef]

**Figure 1.**Sketch of a two-dimensional section of the macula, including choroid and choroid blood vessels, Bruch’s membrane, retinal pigment cells, drusen, outer retina, epithelial cells, and tip cells. Left panel: normal supply of oxygen. Right panel: hypoxia and incipient choroid neovascularization.

**Figure 2.**Effect of impaired adhesion between retinal pigmentation epithelium (RPE) and Bruch’s membrane (BM). Type 1 choroidal neovascularization (CNV) for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE-BM) = 30, snapshots at times: (

**a**) 601 Monte Carlos Time Step (MCTS), (

**d**) 1601 MCTS, (

**g**) 4501 MCTS, (

**j**) 9001 MCTS. Type 2 CNV for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE-BM) = 6, snapshots at times: (

**b**) 601 MCTS, (

**e**) 1601 MCTS, (

**h**) 4501 MCTS, (

**k**) 9001. MCTS. Type 2 CNV for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE-BM) = 0, snapshots at times: (

**c**) 601 MCTS, (

**f**) 1601 MCTS, (

**i**) 4501 MCTS, (

**l**) 9001 MCTS. We have represented the level curves of external VEGF as continuous lines.

**Figure 3.**Effect of impaired adhesion between RPE–RPE and EC–EC. Type 2 CNV for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (EC-EC). = 70 and ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE cell-RPE cell) = 90, snapshots at times: (

**a**) 601 MCTS, (

**d**) 1801 MCTS, (

**g**) 3601 MCTS, (

**j**) 8001 MCTS. Type 1 CNV for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (EC-EC) = 70 and ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE cell-RPE cell) = 80, snapshots at times: (

**b**) 601 MCTS, (

**e**) 1801 MCTS, (

**h**) 3601 MCTS, (

**k**) 8001 MCTS. Type 2 CNV for ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (EC–EC) = 80 and ${\rho}_{adh}^{{\mathsf{\Sigma}}_{\sigma},{\mathsf{\Sigma}}_{{\sigma}^{\prime}}}$ (RPE cell-RPE cell) = 80, snapshots at times: (

**c**) 601 MCTS, (

**f**) 1801 MCTS, (

**i**) 3601 MCTS, (

**l**) 8001 MCTS.

**Figure 4.**Effect of the VEGF concentration at the sources. For αi = 4.01 × 10

^{−4}= 0.000401, snapshots at times: (

**a**) 601 MCTS, (

**d**) 1201 MCTS, (

**g**) 3001 MCTS, (

**j**) 5201 MCTS. For αi = 1.203 × 10

^{−3}= 0.001203, snapshots at times: (

**b**) 601 MCTS, (

**e**) 1201 MCTS, (

**h**) 3001 MCTS, (

**k**) 5201 MCTS. For αi = 2.005 × 10

^{−3}= 0.002005, snapshots at times: (

**c**) 601 MCTS, (

**f**) 1201 MCTS, (

**i**) 3001 MCTS, (

**l**) 5201 MCTS.

**Figure 5.**Type 1 CNV due to the lack of VEGF in the point where the tip cell of the sprout tries to cross the RPE (left column: (

**a**), (

**c**), (

**e**)). Amount of VEGF receptors of ECs (right column: (

**b**), (

**d**), (

**f**)). Snapshots at times: (

**a**), (

**b**) 1501 MCTS, (

**c**), (

**d**) 4501 MCTS, (

**e**), (

**f**) 9001 MCTS.

**Figure 6.**Type 2 CNV favored by the point where the sprout cross the RPE (left column: (

**a**), (

**c**), (

**e**)). Amount of VEGF receptors of ECs (right column: (

**b**), (

**d**), (

**f**)). Snapshots at times: (

**a**), (

**b**) 1201 MCTS, (

**c**), (

**d**) 1501 MCTS, (

**e**), (

**f**) 3001 MCTS.

**Figure 7.**Effect of Jagged and Delta production on CNV. Type 1 CNV for ${r}_{J}$ = 500 molec/h, ${r}_{D}$ = 1000 molec/h, snapshots at times: (

**a**) 601 MCTS, (

**d**) 1601 MCTS, (

**g**) 4501 MCTS, (

**j**) 9001 MCTS. Type 2 CNV (reference simulation) for ${r}_{J}$ = 2000 molec/h, ${r}_{D}$ = 1000 molec/h, snapshots at times: (

**b**) 601 MCTS, (

**e**) 1601 MCTS, (

**h**) 4501 MCTS, (

**k**) 9001 MCTS. Type 2 CNV for ${r}_{J}$ = 2000 molec/h, ${r}_{D}$ = 7500 molec/h, snapshots at times: (

**c**) 601 MCTS, (

**f**) 1601 MCTS, (

**i**) 4501 MCTS, (

**l**) 9001 MCTS. Left column extracted from Supplementary Material: Video S1. Middle column extracted from Supplementary Material: Video S2.

**Figure 8.**Effect of Jagged and Delta production on CNV. Type 1 CNV for ${r}_{J}$ = 500 molec/h, ${r}_{D}$ = 1000 molec/h, snapshots at times: (

**a**) 601 MCTS, (

**d**) 1801 MCTS, (

**g**) 3601 MCTS, (

**j**) 8001 MCTS. Type 2 CNV (reference simulation) for ${r}_{J}$ = 2000 molec/h, ${r}_{D}$ = 1000 molec/h, snapshots at times: (

**b**) 601 MCTS, (

**e**) 1801 MCTS, (

**h**) 3601 MCTS, (

**k**) 8001 MCTS. Type 2 CNV for ${r}_{J}$ = 2000 molec/h, ${r}_{D}$ = 7500 molec/h, snapshots at times: (

**c**) 601 MCTS, (

**f**) 1801 MCTS, (

**i**) 3601 MCTS, (

**l**) 8001 MCTS.

Param. | A_{EC} | P_{EC} | L_{EC} | A_{RPE} | P_{RPE} | A_{druse} | P_{druse} |
---|---|---|---|---|---|---|---|

Value | 78 µm^{2} | 50 µm | 60 µm | 169 µm^{2} | 52 µm | 2827 µm^{2} | 188 µm |

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

## Share and Cite

**MDPI and ACS Style**

Vega, R.; Carretero, M.; Bonilla, L.L.
Anomalous Angiogenesis in Retina. *Biomedicines* **2021**, *9*, 224.
https://doi.org/10.3390/biomedicines9020224

**AMA Style**

Vega R, Carretero M, Bonilla LL.
Anomalous Angiogenesis in Retina. *Biomedicines*. 2021; 9(2):224.
https://doi.org/10.3390/biomedicines9020224

**Chicago/Turabian Style**

Vega, Rocío, Manuel Carretero, and Luis L Bonilla.
2021. "Anomalous Angiogenesis in Retina" *Biomedicines* 9, no. 2: 224.
https://doi.org/10.3390/biomedicines9020224